Phase I Trial of Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary)
- Indications Ewing's sarcoma; Neuroectodermal tumours; Solid tumours; Thyroid cancer
- Focus Adverse reactions
- Sponsors Gradalis
- 09 Apr 2018 Planned End Date changed from 1 Jun 2018 to 1 Aug 2018.
- 09 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Jul 2018.
- 19 Jan 2018 Planned End Date changed from 1 Jan 2018 to 1 Jun 2018.